PrevisEA
Commercial- Indications
- Gastrointestinal impairment
Company intelligence / Profile preview
Entac Medical develops noninvasive wearable devices that use predictive analytics and AI to analyze biological acoustic signals. Their flagship product, PrevisEA, attaches to a patient's abdomen post-surgery to predict downstream adverse events such as gastrointestinal dysfunction. The technology aims to improve patient outcomes by enabling earlier intervention and reducing hospital readmissions and costs. The company’s approach leverages proprietary algorithms and sensor platforms for real-time risk assessment in clinical settings.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Entac Medical.